Produktname:(S)-2-(Boc-amino)-1-propanol
IUPAC Name:tert-butyl N-[(2S)-1-hydroxypropan-2-yl]carbamate
- CAS:79069-13-9
- Molekulare Formel:C8H17NO3
- Reinheit:97%
- Katalognummer:CM116618
- Molekulargewicht:175.23
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:79069-13-9
- Molekulare Formel:C8H17NO3
- Schmelzpunkt:-
- SMILES-Code:C[C@H](NC(OC(C)(C)C)=O)CO
- Dichte:
- Katalognummer:CM116618
- Molekulargewicht:175.23
- Siedepunkt:
- Mdl-Nr.:MFCD00043121
- Lagerung:Keep in a tight container and store at abient temperature
Category Infos
- Aliphatic Chain Compounds
- Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.
Column Infos
- Alcohols
- Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.
- Darolutamide
- Bayer announced that its Phase 3 clinical ARANOTE trial met its primary endpoint. Its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) combined with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA® (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to androgen receptors with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.